Sandoz wins European approval of EPO biosimilar
Executive Summary
The Novartis subsidiary's epoetin alfa follow-on Binocrit, which received European marketing approval Aug. 31, will be priced at a 25 to 30 percent discount to innovator products, Sandoz exec Ajaz Hussain tells "The Pink Sheet." The first launch will be in Germany in September. Sandoz is maintaining its lead in biosimilars; Binocrit is the first approval for biosimilar EPO, although positive opinions have been issued for products from Hexal Biotech Forschungs (another Novartis business unit) and Medice Arzneimittel Putter. Sandoz was first to market with a biosimilar human growth hormone, Omnitrope (1"The Pink Sheet" June 5, 2006, p. 3)...
You may also be interested in...
Amgen Seeks U.K. Ban On Biosimilar Interchangeability With Innovator Product
Amgen has won the support of several U.K. legislators who are advocating a ban on the automatic substitution of innovator biopharmaceuticals, but it appears unlikely the British government will impose such a prohibition
Amgen’s European EPO Sales Unaffected By Biosimilars, Company Says
The European launch of biosimilar erythropoietin products has failed to impact European sales of Amgen's EPO products, EVP Worldwide Sales and Marketing George Morrow said during the company's third quarter earnings call Oct. 24
FDA Clears Omnitrope; Product Is Not The Process, But Nor Is It A Pathway
Sandoz' approval for the first follow-on version of a human growth hormone product relies on data from a Phase III clinical program that studied 89 pediatric patients